Philips takes on EDDA's lung cancer detection software:
This article was originally published in Clinica
Executive Summary
Philips Medical Systems, the medical imaging arm of Dutch electronics giant Philips, is to add Princeton Junction, New Jersey-based EDDA Technology's IQQA-Chest software to its family of digital radiography products following a licensing agreement. The diagnostic imaging tool, designed to identify, quantify and evaluate lesions in the lung, has been shown to increase the discovery rates of small, early-stage nodules by over 85% compared to detection without IQQA assistance, which varies between 35-65%, claimed Philips. The FDA-cleared IQQA-Chest will be sold in combination with Philips' entire range of digital radiography systems in the US and China and will become available in additional countries from 2007.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.